A wise leader once told me: going fast is great, but real success lies in predictability. As we discuss the “4Ps” of R&D leadership, Planning, People, Process, and Projects, it becomes clear that Predictability is the true differentiator for organizations striving to meet their commitments and outperform competitors.
Today, technical skillsets are more accessible than ever. Tools, training, outsourcing, and shared market knowledge have leveled the playing field. Competitors often understand the same unmet needs and have access to similar capabilities.
So how does a firm truly outperform when skillsets are broadly available? It comes down to human capital and judgment.
The most innovative medtech companies I’ve seen share a common trait: they cultivate environments where engineering, marketing, clinical, and quality teams work together with a sense of shared accountability. They don’t want to let each other down, and that discretionary effort is what moves programs forward.
R&D leaders must identify what is needed, ensure the right tools and skillsets are in place, and unlock the full potential of their teams. Intrinsic motivation is abundant in medtech. We are fortunate to work on life-saving and life-improving technologies. But even highly motivated engineers can struggle if they are in the wrong role, navigating cumbersome systems, or dealing with inconsistent decision-making.
Great leaders recognize this. They place people in roles aligned with their strengths, eliminate unnecessary processes, and remove the “rocks in the shoes” that slow teams down. Clear, consistent communication reinforces this environment. Shame and rushed ambition, on the other hand, suppress learning, innovation, and teamwork.
Once the right people are in the right roles, the question becomes: how do you build judgment?
The answer is simple: give people an emotionally safe place to fail. Judgment is formed through repeated cycles of trying, failing, learning, and trying again. We write our resumes with our successes, but our failures are what shape our judgment. Over the years, I have intentionally placed strong leaders who have failed openly back into similar roles. With coaching and support, they become some of the most motivated and capable leaders in the organization. Their intrinsic drive to “get it right” becomes a powerful force for the team.
And we should not overlook non-work experiences. Life shapes judgment just as much as work does, and tapping into the whole person often unlocks remarkable insight.
Early in my career, I learned a hard lesson about introducing new technology into manufacturing. Many manufacturing floors are unintentionally disincentivized to adopt new processes; new technology takes longer, increases reject rates, and can reduce profitability per square foot. Simply setting a goal for “new product launches” is not enough to ensure a smooth transfer.
Experience and judgment teach you that Design for Manufacturability and early pilot runs are essential. Strong R&D leaders recognize which engineers have this instinct and bring them into DfM roles early, even if the standard process does not call for it yet.
A new technology will never be fully optimized for manufacturability on day one. But the strategic value of the innovation may justify a temporary hit to manufacturing KPIs. Understanding that tradeoff, and exploring it early, is exactly where good judgment matters most.
When teams are under pressure to launch faster, one of the longest stretches in any medical device timeline is the creation, submission, and clearance or approval of the device. It is consistently the area where leaders look to save time, and equally, one of the most important places where experience and good judgment must be applied.
If you work in an established firm with a mature product portfolio, the testing portion of a submission is typically developed by the R&D team and may rely, at least in part, on the concept of “history of safe use.” In practice, this means that certain elements of your design intent may not require retesting, because decades of real-world use, typically 25 years or more, can demonstrate that the device performs safely as intended.
That said, the reason a new filing is being submitted in the first place is usually a change that cannot be supported by history of safe use, or one that departs meaningfully from the cleared design. When the justification and data package are solid, the timeline for that submission can be significantly compressed.
The challenge is that agencies and notified bodies don’t always agree. On more than one occasion, I have seen months, and in some cases years, added to a program timeline because key data was overestimated and critical safety evidence was deemed insufficient. Once an agency or competent authority determines that the justification doesn’t hold, there is very little you can do to recover quickly.
Good judgment here means identifying those high-risk elements early, pressure-testing your justification through pre-submission meetings with the FDA or relevant competent authority, and running full design validation and verification in parallel so that data is ready to submit if the primary justification fails. Additional practices worth building into your cadence include retesting when standards are updated and running periodic full validation and verification cycles to maintain process controls and build a predictable dataset. If your requirements can be tied to a summative usability test that executes quickly, that too can meaningfully accelerate the path to clearance.
These approaches carry cost and require careful balancing; they can occasionally produce confounding results. But the goal is predictability, and achieving an expedited clearance date is one of the clearest wins an R&D leader can deliver.
If you find yourself in the position of having to withdraw a submission, add testing, and resubmit, expect timeline slippage of at least one to two quarters. It is also common in that moment for leaders to reason: “If I have to redo the testing anyway, I might as well add this other change and get it cleared at the same time.” Resist that impulse. Testing changes in isolation, with and without additional modifications, is the disciplined path. Bundling changes mid-recovery is the definition of scope creep, and scope creep is the death knell of predictability. Use good judgment, and communicate widely.
Terri Kapur is a seasoned R&D executive with more than 20 years of experience driving innovation in the medical device industry. She has led global, multidisciplinary teams across the full product lifecycle, from early research through development, commercialization, and post-market support.
